What question did this study set out to answer?

Compare the efficacy and safety of lenalidomide plus high-dose dexamethasone versus placebo plus high-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma.

September 28, 2010BloodOpen Access

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

View Full Paper

Ask AI

Bookmark

Compare the efficacy and safety of lenalidomide plus high-dose dexamethasone versus placebo plus high-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma.
Multicenter randomized trial (SWOG S0232, NCT00064038) allocating patients with newly diagnosed myeloma to lenalidomide plus dexamethasone (n = 97) or placebo plus dexamethasone (n = 95).
Induction comprised three 35-day cycles of dexamethasone (40 mg/day on days 1–4, 9–12, and 17–20) with lenalidomide (25 mg/day for 28 days) or placebo, followed by monthly maintenance and permitted crossover upon disease progression.
Lenalidomide plus dexamethasone significantly improved 1-year progression-free survival (78% vs 52%, P = .002), overall response rate (78% vs 48%, P < .001), and very good partial response rate (63% vs 16%, P < .001), while 1-year overall survival was 94% vs 88% (P = .25).
Grade 3 or 4 neutropenia occurred in 21% of the lenalidomide-dexamethasone group versus 5% with placebo-dexamethasone (P < .001).
Thromboembolic events occurred in 23.5% of patients exposed to lenalidomide-dexamethasone compared with 5% receiving placebo-dexamethasone (P < .001), despite aspirin prophylaxis.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial finds superior progression-free survival with lenalidomide plus dexamethasone in multiple myeloma, highlighting greater disease control despite increased toxicity.

Cite This Study

Zonder et al. (2010) studied this question.

synapsesocial.com/papers/6a0da59cfb8c7be8ffba77cb https://doi.org/10.1182/blood-2010-08-303487

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial finds superior progression-free survival with lenalidomide plus dexamethasone in multiple myeloma, highlighting greater disease control despite increased toxicity.

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

Key Points

Discussion

Implication

Cite This Study

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider